Amylyx Pharmaceuticals Ownership | Who Owns Amylyx Pharmaceuticals?


OverviewForecastFinancialsChartTranscripts

Amylyx Pharmaceuticals Ownership Summary


Amylyx Pharmaceuticals is owned by 11.99% institutional investors, 7.91% insiders, and 80.09% retail investors. Fmr is the largest institutional shareholder, holding 17.59% of AMLX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.81% of its assets in Amylyx Pharmaceuticals shares.

AMLX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAmylyx Pharmaceuticals11.99%7.91%80.09%
SectorHealthcare Stocks 35.34%11.88%52.77%
IndustryBiotech Stocks 35.37%11.83%52.80%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr16.63M17.59%$231.16M
Blackrock funding, inc. /de8.83M9.34%$122.72M
Perceptive advisors8.28M8.76%$115.16M
Tcg crossover management6.24M6.60%$86.79M
Vanguard group5.80M6.22%$70.12M
Commodore capital lp5.65M5.97%$78.53M
Janus henderson group4.99M5.27%$69.26M
Saturn v capital management4.35M4.60%$60.46M
Blackrock2.67M3.93%$5.07M
Adage capital partners gp3.56M3.77%$49.49M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Saturn v capital management4.35M10.95%$60.46M
Allostery investments lp120.12K9.81%$769.96K
Almitas capital2.12M6.67%$29.50M
Great point partners1.75M5.59%$24.32M
Commodore capital lp5.65M4.54%$78.53M
First light asset management3.19M3.97%$44.35M
Ally bridge group (ny)437.39K3.62%$5.94M
Tcg crossover management6.24M2.48%$86.79M
Perceptive advisors8.28M2.25%$115.16M
Aldebaran capital197.89K2.10%$2.75M

Top Buyers

HolderShares% AssetsChange
Paradigm biocapital advisors lp1.90M0.73%1.90M
Siren1.23M0.47%1.23M
Franklin resources2.26M0.01%1.06M
Adage capital partners gp3.56M0.08%783.71K
Barclays971.85K0.00%676.68K

Top Sellers

HolderShares% AssetsChange
Blackrock2.67M0.00%-1.80M
Boxer capital---1.50M
Farallon capital management---1.15M
Alyeska investment group---750.41K
Abrdn---738.66K

New Positions

HolderShares% AssetsChangeValue
Paradigm biocapital advisors lp1.90M0.73%1.90M$25.82M
Siren1.23M0.47%1.23M$17.10M
Braidwell lp612.84K0.25%612.84K$8.33M
Vanguard fiduciary trust586.15K0.00%586.15K$8.15M
Ally bridge group (ny)437.39K3.62%437.39K$5.94M

Sold Out

HolderChange
Ifp advisors-1.00
Nelson, van denburg & campbell wealth management group-10.00
Financial consulate-25.00
Kelly financial services-33.00
Skopos labs-42.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202667-64.74%11,342,671-89.90%110.08%27-75.23%25-46.81%
Dec 31, 2025114-35.23%37,817,895-65.53%400.27%65-38.10%25-46.81%
Sep 30, 202517034.92%109,563,43439.61%1221.59%10146.38%4643.75%
Jun 30, 2025131-2.96%81,652,43717.21%911.39%70-12.50%3512.90%
Mar 31, 20251373.79%73,635,54347.89%851.61%8224.24%30-26.83%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.10M2.81%-
Fidelity Advisor Biotechnology I2.43M2.19%-
iShares Russell 2000 ETF2.16M1.94%18.19K
Fidelity Small Cap Growth2.12M1.90%-
Eventide Healthcare & Life Sciences I1.51M1.37%-
Fidelity Select Health Care1.42M1.28%-
Xtrackers S&P 500 Swap ETF 1C1.24M1.13%-9.15K
Fidelity Select Biotechnology1.22M1.10%-
Strategic Advisers Fidelity US TtlStk1.14M1.02%-
Franklin Biotechnology Discv A(acc)USD1.11M1.00%82.08K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 02, 2026Klee Justin B. Co-Chief Executive OfficerSell$423.76K
Mar 02, 2026Cohen Joshua B Co-Chief Executive OfficerSell$424.12K
Mar 02, 2026Bedrosian Camille L Chief Medical OfficerSell$94.21K
Mar 02, 2026FRATES JAMES M Chief Financial OfficerSell$114.85K
Mar 02, 2026Mazzariello Gina Chief Legal OfficerSell$99.38K

Insider Transactions Trends


DateBuySell
2026 Q1-17
2025 Q411
2025 Q3-9
2025 Q2--
2025 Q1114

AMLX Ownership FAQ


Who Owns Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals shareholders are primarily institutional investors at 11.99%, followed by 7.91% insiders and 80.10% retail investors. The average institutional ownership in Amylyx Pharmaceuticals's industry, Biotech Stocks , is 35.37%, which Amylyx Pharmaceuticals falls below.

Who owns the most shares of Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals’s largest shareholders are Fmr (16.63M shares, 17.59%), Blackrock funding, inc. /de (8.83M shares, 9.34%), and Perceptive advisors (8.28M shares, 8.76%). Together, they hold 35.68% of Amylyx Pharmaceuticals’s total shares outstanding.

Does Blackrock own Amylyx Pharmaceuticals?

Yes, BlackRock owns 3.93% of Amylyx Pharmaceuticals, totaling 2.67M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 5.07M$. In the last quarter, BlackRock decreased its holdings by -1.805M shares, a -40.34% change.

Who is Amylyx Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Saturn v capital management is Amylyx Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 10.95% of its assets in 4.35M Amylyx Pharmaceuticals shares, valued at 60.46M$.

Who is the top mutual fund holder of Amylyx Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Amylyx Pharmaceuticals shares, with 2.81% of its total shares outstanding invested in 3.1M Amylyx Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools